Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

Cancer

Volumn 91, Issue 7, 2001, Pages 1191-1200

  Berenson, James R ^a,j   Rosen, Lee S ^b   Howell, Anthony ^c   Porter, Lester ^d   Coleman, Robert E ^e   Morley, Walter ^f   Dreicer, Robert ^g   Kuross, Steven A ^h   Lipton, Allan ⁱ   Seaman, John J ^j  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d Saint Thomas Medical Partners   (United States)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f American Medical Research Institute   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Duluth Clinic   (United States)

ⁱ PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Bisphosphonates; Bone metastases; Cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PAIN MEASUREMENT; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 0035312469     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0     Document Type: Article

References (29)

1. Anatomy and pathways of skeletal metastases
2. Treatment of metastatic cancer to bone
3. Role of cytokines, parathyroid hormone, and growth factors in malignancy
4. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
5. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
6. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: A pilot study
7. Radiation therapy in the management of symptomatic bone metastases: The effect of total dose and histology on pain relief and response duration
8. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases
9. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
10. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term followup of two randomized placebo-controlled trials
11. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
12. Renal tolerability profile of novel, potent, bisphosphonates in 2 short-term rat models
13. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - A pooled analysis of two randomized, controlled clinical trials
14. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
15. Phase I open label, dose ranging, safety trial of rapid intravenous zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone metastases
16. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
17. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions. A randomized, placebo-controlled trial - Protocol 18 Aredia Breast Cancer Study Group
18. Pain assessment: Global use of the Brief Pain Inventory
19. Bisphosphonates and breast carcinoma
20. Biologic and therapeutic determinants of bone mineral density in multiple myeloma
21. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
22. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
23. Markers of bone resorption in patients treated with pamidronate
24. High dose pamidronate - Clinical and biochemical effects in metastatic bone disease
25. Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
26. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene disphosphonate, APD) as single shot treatment of hypercalcaemia
27. Ibandronate in oncology
28. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate